Across the past 12 months, Brainstorm Cell Therapeutics insiders reported no open-market purchases or sales.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Jacob A Frenkel | Director | 343,777 | 0 | 343,777 | 35.7% | 28 Jul, 2026 |
| 2 | Chaim Lebovits | President Ceo | 200,960 | 0 | 200,960 | 20.8% | 03 Jan, 2025 |
| 3 | Uri Yablonka | Evp Chief Business Officer | 68,464 | 0 | 68,464 | 7.1% | 03 Jan, 2025 |
| 4 | Ibrahim B. Dagher | Chief Medical Officer | 66,849 | 0 | 66,849 | 6.9% | 07 Jan, 2025 |
| 5 | Hartoun Hartounian | Evp, Chief Operating Officer | 52,000 | 0 | 52,000 | 5.4% | 03 Jan, 2025 |
| 6 | Stacy Lindborg | Co Chief Executive Officer | 48,229 | 0 | 48,229 | 5.0% | 03 Jan, 2025 |
| 7 | Alla Patlis | Officer | 44,349 | 0 | 44,349 | 4.6% | 03 Jan, 2025 |
| 8 | Irit Arbel | Director | 41,054 | 0 | 41,054 | 4.3% | 03 Jan, 2025 |
| 9 | Nir Naor | Director | 31,465 | 0 | 31,465 | 3.3% | 03 Jan, 2025 |
| 10 | Anthony J. Polverino | Director | 25,730 | 0 | 25,730 | 2.7% | 03 Jan, 2025 |
| 11 | Menghisteab Bairu | Director | 24,000 | 0 | 24,000 | 2.5% | 03 Jan, 2025 |
| 12 | Ralph Dr. Kern | Coo And Chief Medical Officer | 14,888 | 0 | 14,888 | 1.5% | 14 Mar, 2022 |
| 13 | Kirk Taylor | Chief Medical Officer | 2,333 | 0 | 2,333 | 0.2% | 01 May, 2023 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 24 Jul, 2026 | Jacob A Frenkel | Director | Acquired A | 100,000 | $0.00 | $0 | 343,777 | Direct |
| 24 Jul, 2026 | Peter Joe Pitts | Executive Chairman | Acquired A | 900,000 | $0.00 | $0 | 900,000 | Direct |
| 01 Jan, 2025 | Ibrahim B. Dagher | Chief Medical Officer | Acquired A | 50,000 | $0.00 | $0 | 66,849 | Direct |
| 01 Jan, 2025 | Uri Yablonka | Evp Chief Business Officer | Acquired A | 40,000 | $0.00 | $0 | 48,464 | Direct |
| 01 Jan, 2025 | Irit Arbel | Director | Acquired A | 30,666 | $0.00 | $0 | 41,054 | Direct |
| 01 Jan, 2025 | Anthony J. Polverino | Director | Acquired A | 24,000 | $0.00 | $0 | 25,730 | Direct |
| 01 Jan, 2025 | Chaim Lebovits | President Ceo | Acquired A | 120,000 | $0.00 | $0 | 200,960 | Direct |
| 01 Jan, 2025 | Jacob A Frenkel | Director | Acquired A | 40,000 | $0.00 | $0 | 43,777 | Direct |
| 01 Jan, 2025 | Hartoun Hartounian | Evp, Chief Operating Officer | Acquired A | 50,000 | $0.00 | $0 | 52,000 | Direct |
| 01 Jan, 2025 | Stacy Lindborg | Director | Acquired A | 20,000 | $0.00 | $0 | 48,229 | Direct |
| 01 Jan, 2025 | Alla Patlis | Officer | Acquired A | 40,000 | $0.00 | $0 | 44,349 | Direct |
| 01 Jan, 2025 | Menghisteab Bairu | Director | Acquired A | 24,000 | $0.00 | $0 | 24,000 | Direct |
| 01 Jan, 2025 | Nir Naor | Director | Acquired A | 30,666 | $0.00 | $0 | 31,465 | Direct |
| 01 Jan, 2025 | Uri Yablonka | Evp Chief Business Officer | Acquired A | 20,000 | $0.00 | $0 | 68,464 | Direct |
| 30 Sep, 2024 | Chaim Lebovits | President Ceo | Acquired P | 22,000 | $3.42 | $75.24K | 79,128 | Direct |
| 01 Oct, 2024 | Chaim Lebovits | President Ceo | Acquired P | 1,836 | $3.43 | $6.29K | 80,960 | Direct |
| 28 May, 2024 | Chaim Lebovits | President Ceo | Acquired P | 15,000 | $7.77 | $116.61K | 77,662 | Direct |
| 21 May, 2024 | Chaim Lebovits | President Ceo | Acquired P | 25,000 | $8.68 | $217.12K | 74,995 | Direct |
| 22 May, 2024 | Chaim Lebovits | President Ceo | Acquired P | 25,000 | $9.60 | $239.99K | 76,662 | Direct |
| 19 Jul, 2024 | Ibrahim B. Dagher | Chief Medical Officer | Disposed S | 63,000 | $5.25 | $331.01K | 0 | Direct |